{"cik":1671584,"taxonomy":"us-gaap","tag":"AmortizationOfIntangibleAssets","label":"Amortization of Intangible Assets","description":"The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.","entityName":"Aptevo Therapeutics Inc.","units":{"USD":[{"start":"2015-01-01","end":"2015-06-30","val":896000,"accn":"0000950123-16-020493","fy":2016,"fp":"Q2","form":"10-Q/A","filed":"2016-09-22"},{"start":"2015-01-01","end":"2015-12-31","val":3400000,"accn":"0001564590-17-005738","fy":2016,"fp":"FY","form":"10-K","filed":"2017-03-31","frame":"CY2015"},{"start":"2016-01-01","end":"2016-06-30","val":1173000,"accn":"0000950123-16-020493","fy":2016,"fp":"Q2","form":"10-Q/A","filed":"2016-09-22"},{"start":"2016-01-01","end":"2016-12-31","val":2200000,"accn":"0001564590-17-005738","fy":2016,"fp":"FY","form":"10-K","filed":"2017-03-31"},{"start":"2016-01-01","end":"2016-12-31","val":800000,"accn":"0001564590-18-005384","fy":2017,"fp":"FY","form":"10-K","filed":"2018-03-13","frame":"CY2016"},{"start":"2017-01-01","end":"2017-12-31","val":800000,"accn":"0001564590-18-005384","fy":2017,"fp":"FY","form":"10-K","filed":"2018-03-13"},{"start":"2017-01-01","end":"2017-12-31","val":800000,"accn":"0001564590-19-008184","fy":2018,"fp":"FY","form":"10-K","filed":"2019-03-18","frame":"CY2017"},{"start":"2018-01-01","end":"2018-12-31","val":800000,"accn":"0001564590-19-008184","fy":2018,"fp":"FY","form":"10-K","filed":"2019-03-18","frame":"CY2018"},{"start":"2019-01-01","end":"2019-12-31","val":800000,"accn":"0001564590-20-012791","fy":2019,"fp":"FY","form":"10-K","filed":"2020-03-25","frame":"CY2019"}]}}